文献速递关节外科

全膝关节置换术后深静脉血栓预防的趋势:2016年至2021年

Trends in Deep Vein Thrombosis Prophylaxis After Total Knee Arthroplasty: 2016 to 2021.
PubMed 文献 · J Arthroplasty · 2024-02-05

基于2016至2021年全国全付款方数据库,分析初次全膝关节置换术后静脉血栓栓塞预防用药趋势及90天并发症。阿司匹林使用率从32.1%升至70.8%,华法林从19.3%降至3.0%。华法林组肺栓塞(1.8%)和深静脉血栓(5.7%)发生率最高,阿司匹林组最低(0.6%和1.6%)。依诺肝素、利伐沙班和华法林是90天总并发症的独立危险因素。

要点

  • 2016至2021年阿司匹林使用率从32.1%升至70.8%,华法林从19.3%降至3.0%。
  • 华法林组肺栓塞1.8%、深静脉血栓5.7%最高,阿司匹林组0.6%、1.6%最低。
  • 依诺肝素、利伐沙班和华法林是90天总并发症的独立危险因素。

核心结论

  • 2016至2021年全国代表性人群中,全膝关节置换术后阿司匹林用于静脉血栓栓塞预防的使用率增加,其他抗凝药 cohort 相对减少。

研究设计与样本

  • 使用2016至2021年全国全付款方数据库,纳入所有初次全膝关节置换术患者,排除术前1年内使用抗凝药、高凝状态和癌症患者。
  • 收集各静脉血栓栓塞预防队列的基线人口学(年龄、性别、糖尿病、合并症指数)及术后肺栓塞、深静脉血栓和输血率,并进行多变量回归分析90天总并发症的独立危险因素。

主要发现

  • 2016至2021年阿司匹林使用最多(n=62,054),其次为利伐沙班(n=26,426)、依诺肝素(n=20,980)和华法林(n=13,305)。
  • 华法林组肺栓塞发生率1.8%、深静脉血栓5.7%最高,阿司匹林组肺栓塞0.6%、深静脉血栓1.6%最低。
  • 阿司匹林使用率从2016年32.1%升至2021年70.8%,华法林从19.3%降至3.0%。
  • 依诺肝素、利伐沙班和华法林是90天总并发症的独立危险因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In 2011, the American Academy of Orthopaedic Surgeons released a consensus recommending venous thromboembolism (VTE) prophylaxis after total knee arthroplasty (TKA). The purpose of our study was to examine (1) incidences of postoperative complications, including pulmonary embolism (PE), deep vein thrombosis (DVT), and transfusion rates; (2) trends from 2016 to 2021 in VTE prophylaxis; and (3) independent risk factors for 90-day total complications following TKA between aspirin, enoxaparin, rivaroxaban, and warfarin. METHODS: Using a national, all-payer database from 2016 to 2021, we identified all patients who underwent primary TKA. Exclusions included all patients who had prescribed anticoagulants within 1 year prior to TKA, hypercoagulable states, and cancer. Data were collected on baseline demographics, including age, sex, diabetes, and a comorbidity index, in each of the VTE prophylaxis cohorts. Postoperative outcomes included rates of PE, DVT, and transfusion. Multivariable regressions were performed to determine independent risk factors for total complications at 90 days following TKA. RESULTS: From 2016 to 2021, aspirin was the most used anticoagulant (n = 62,054), followed by rivaroxaban (n = 26,426), enoxaparin (n = 20,980), and warfarin (n = 13,305). The cohort using warfarin had the highest incidences of PE (1.8%) and DVT (5.7%), while the cohort using aspirin had the lowest incidences of PE (0.6%) and DVT (1.6%). The rates of aspirin use increased the most from 2016 to 2021 (32.1% to 70.8%), while the rates of warfarin decreased the most (19.3% to 3.0%). Enoxaparin, rivaroxaban, and warfarin were independent risk factors for total complications at 90 days. CONCLUSIONS: An epidemiological analysis of VTE prophylaxis use from 2016 to 2021 shows an increase in aspirin following TKA compared to other anticoagulant cohorts in a nationally representative population. This approach provides more insight and a better understanding of anticoagulation trends over this time period in a nationally representative sample.

来源:J Arthroplasty,查看原文。版权归原作者所有。

引用

  1. Dubin JA, Bains SS, Hameed D, et al. Trends in Deep Vein Thrombosis Prophylaxis After Total Knee Arthroplasty: 2016 to 2021. J Arthroplasty. 2024. PMID: 38325530. doi:10.1016/j.arth.2024.01.050

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。